Healthcare Regulation (HIPAA)

Quoin Pharmaceuticals files the first-ever drug application for Peeling Skin Syndrome, offering a glimmer of hope for patients with no treatment options.

Co-Diagnostics is developing a point-of-care Ebola test promising 30-minute results. But can it navigate regulatory hurdles and reach the front lines in time?

As AI and cyber risks escalate, the new 'Chief Trust Officer' role is emerging. HITRUST's appointment of a veteran leader signals a major shift for all.

A novel probiotic, sourced from an elite athlete's gut, has navigated the FDA's complex regulatory maze, signaling a major shift for the entire industry.

A new partnership is democratizing science for wellness brands, making it faster and cheaper to prove their final products work and earn customer trust.

With dual FDA clearances secured, Rhythm AI appoints serial acquirer Mike Dineen as CEO, signaling a strategic pivot from innovation to market conquest.

A surprising innovation is changing surgical recovery. New research shows preoperative Botox can halve opioid use for jaw surgery patients. A breakthrough?

A federal ruling offers a lifeline to detained immigrants in the Midwest, but attorneys warn that the real dangers lie in everyday life and a fractured legal system.

Shanti Recovery & Wellness gains DHCS accreditation, launching a virtual IOP that combines clinical therapy with holistic practices for California adults.

The FDA just granted Orphan Drug status to a promising ALS therapy. It's a beacon of hope for patients and a masterclass in biotech strategy.

Aethlon Medical's upcoming financial report is more than a balance sheet; it's a test of viability for its revolutionary Hemopurifier blood filter.

A pivotal trial completes enrollment at a record pace while the AMA lays the groundwork for billing. ShiraTronics is rewriting the medtech playbook.

While competitors build complex apps, Maxwell TEC is winning the home care market with simple SMS. Their milestone is a strategic signal for patient engagement.

AbbVie secures EU approval for AQUIPTA as an acute migraine therapy, creating a dual-use drug that challenges rivals and reshapes patient care strategy.

Healthcare AI firm RAAPID achieves the 'gold standard' HITRUST r2 certification, signaling a major shift in data protection for sensitive patient information.

A Tulsa jury found a doctor negligent, awarding $15M to a girl left with severe brain damage after a missed diagnosis of bacterial meningitis as an infant.

Wellness brand Le-Vel is launching a telehealth service for prescription peptides, blurring the lines between direct sales and mainstream medicine.

ITG Brands acquires innovator Black Buffalo for $150M, diversifying beyond nicotine pouches to capture a new segment of smokeless alternative users.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

Positive Phase 3 data for oral drug filgotinib offers new hope for thousands of axial spondyloarthritis patients who fail to respond to current therapies.